Exact Mass: 545.263806
Exact Mass Matches: 545.263806
Found 500 metabolites which its exact mass value is equals to given mass value 545.263806
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
N-[(3a,5b,7a,12a)-3,12-dihydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-Glycine
N-[(3a,5b,7a,12a)-3,12-dihydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-Glycine is an acyl glycine and a sulfated bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID:16949895). As a bile acid sulfate, N-[(3a,5b,7a,12a)-3,12-dihydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-Glycine is typically found in urine. These conjugates are formed as a part of detoxification of endogenous and exogenous components in the body (PMID:3584362). [HMDB] N-[(3a,5b,7a,12a)-3,12-dihydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-Glycine is an acyl glycine and a sulfated bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID: 16949895). As a bile acid sulfate, N-[(3a,5b,7a,12a)-3,12-dihydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-Glycine is typically found in urine. These conjugates are formed as a part of detoxification of endogenous and exogenous components in the body (PMID:3584362).
N-[(3a,5b,7a,12a)-3,7-dihydroxy-24-oxo-12-(sulfooxy)cholan-24-yl]-Glycine
N-[(3a,5b,7a,12a)-3,7-dihydroxy-24-oxo-12-(sulfooxy)cholan-24-yl]-Glycine is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID:16949895) [HMDB] N-[(3a,5b,7a,12a)-3,7-dihydroxy-24-oxo-12-(sulfooxy)cholan-24-yl]-Glycine is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID: 16949895).
Glycocholic acid 3-sulfate
homoharringtonine
17-Aminogeldanamycin
Omacetaxine_mepesuccinate
Omacetaxine mepesuccinate is a cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia. It has a role as an antineoplastic agent, a protein synthesis inhibitor, an apoptosis inducer and an anticoronaviral agent. It is an alkaloid ester, a tertiary alcohol, an organic heteropentacyclic compound and an enol ether. It is functionally related to a cephalotaxine. Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. Omacetaxine mepesuccinate is a natural product found in Cephalotaxus harringtonia and Cephalotaxus fortunei with data available. Omacetaxine Mepesuccinate is a semisynthetic formulation of the cytotoxic plant alkaloid homoharringtonine isolated from the evergreen tree Cephalotaxus with potential antineoplastic activity. Omacetaxine binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This agent also induces differentiation and apoptosis in some cancer cell types. Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC. See also: Omacetaxine (has active moiety). A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia. D000970 - Antineoplastic Agents > D000972 - Antineoplastic Agents, Phytogenic > D006248 - Harringtonines C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product C1907 - Drug, Natural Product Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation. Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation.
homoharringtonine
D000970 - Antineoplastic Agents > D000972 - Antineoplastic Agents, Phytogenic > D006248 - Harringtonines C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2287 C1907 - Drug, Natural Product relative retention time with respect to 9-anthracene Carboxylic Acid is 0.650 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.645 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.646 Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation. Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation.
Phe Ser His Arg
Arg Asn Gln Glu
Arg Gln Asn Glu
N-[(3a,5b,7a,12a)-7,12-Dihydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]glycine
BA-148-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-148-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-148-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-148-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-148-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
Ala His Arg Tyr
Ala His Tyr Arg
Ala Asn Arg Trp
Ala Asn Trp Arg
Ala Arg His Tyr
Ala Arg Asn Trp
Ala Arg Trp Asn
Ala Arg Tyr His
Ala Trp Asn Arg
Ala Trp Arg Asn
Ala Tyr His Arg
Ala Tyr Arg His
Asp Phe His Lys
Asp Phe Lys His
Asp His Phe Lys
Asp His Lys Phe
Asp Lys Phe His
Asp Lys His Phe
Asp Gln Gln Arg
Asp Gln Arg Gln
Asp Arg Gln Gln
Glu Glu Ile Arg
Glu Glu Leu Arg
Glu Glu Arg Ile
Glu Glu Arg Leu
Glu Ile Glu Arg
Glu Ile Arg Glu
Glu Leu Glu Arg
Glu Leu Arg Glu
Glu Asn Gln Arg
Glu Asn Arg Gln
Glu Gln Asn Arg
Glu Gln Arg Asn
Glu Arg Glu Ile
Glu Arg Glu Leu
Glu Arg Ile Glu
Glu Arg Leu Glu
Glu Arg Asn Gln
Glu Arg Gln Asn
Phe Asp His Lys
Phe Asp Lys His
Phe His Asp Lys
Phe His Lys Asp
Phe His Arg Ser
Phe His Ser Arg
Phe Lys Asp His
Phe Lys His Asp
Phe Pro Pro Trp
Phe Pro Trp Pro
Phe Arg His Ser
Phe Arg Ser His
Phe Ser Arg His
Phe Trp Pro Pro
Gly Gln Arg Trp
Gly Gln Trp Arg
Gly Arg Gln Trp
Gly Arg Trp Gln
Gly Trp Gln Arg
Gly Trp Arg Gln
His Ala Arg Tyr
His Ala Tyr Arg
His Asp Phe Lys
His Asp Lys Phe
His Phe Asp Lys
His Phe Lys Asp
His Phe Arg Ser
His Phe Ser Arg
His His Pro Arg
His His Arg Pro
His Ile Asn Tyr
His Ile Tyr Asn
His Lys Asp Phe
His Lys Phe Asp
His Lys Met Met
His Leu Asn Tyr
His Leu Tyr Asn
His Met Lys Met
His Met Met Lys
His Asn Ile Tyr
His Asn Leu Tyr
His Asn Tyr Ile
His Asn Tyr Leu
His Pro His Arg
His Pro Arg His
His Gln Val Tyr
His Gln Tyr Val
His Arg Ala Tyr
His Arg Phe Ser
His Arg His Pro
His Arg Pro His
His Arg Ser Phe
His Arg Tyr Ala
His Ser Phe Arg
His Ser Arg Phe
His Val Gln Tyr
His Val Tyr Gln
His Tyr Ala Arg
His Tyr Ile Asn
His Tyr Leu Asn
His Tyr Asn Ile
His Tyr Asn Leu
His Tyr Gln Val
His Tyr Arg Ala
His Tyr Val Gln
Ile Glu Glu Arg
Ile Glu Arg Glu
Ile His Asn Tyr
Ile His Tyr Asn
Ile Met Pro Trp
Ile Met Trp Pro
Ile Asn His Tyr
Ile Asn Asn Trp
Ile Asn Trp Asn
Ile Asn Tyr His
Ile Pro Met Trp
Ile Pro Trp Met
Ile Arg Glu Glu
Ile Trp Met Pro
Ile Trp Asn Asn
Ile Trp Pro Met
Ile Tyr His Asn
Ile Tyr Asn His
Lys Asp Phe His
Lys Asp His Phe
Lys Phe Asp His
Lys Phe His Asp
Lys His Asp Phe
Lys His Phe Asp
Lys His Met Met
Lys Met His Met
Lys Met Met His
Leu Glu Glu Arg
Leu Glu Arg Glu
Leu His Asn Tyr
Leu His Tyr Asn
Leu Met Pro Trp
Leu Met Trp Pro
Leu Asn His Tyr
Leu Asn Asn Trp
Leu Asn Trp Asn
Leu Asn Tyr His
Leu Pro Met Trp
Leu Pro Trp Met
Leu Arg Glu Glu
Leu Trp Met Pro
Leu Trp Asn Asn
Leu Trp Pro Met
Leu Tyr His Asn
Leu Tyr Asn His
Met His Lys Met
Met His Met Lys
Met Ile Pro Trp
Met Ile Trp Pro
Met Lys His Met
Met Lys Met His
Met Leu Pro Trp
Met Leu Trp Pro
Met Met His Lys
Met Met Lys His
Met Pro Ile Trp
Met Pro Leu Trp
Met Pro Trp Ile
Met Pro Trp Leu
Met Trp Ile Pro
Met Trp Leu Pro
Met Trp Pro Ile
Met Trp Pro Leu
Asn Ala Arg Trp
Asn Ala Trp Arg
Asn Glu Gln Arg
Asn Glu Arg Gln
Asn His Ile Tyr
Asn His Leu Tyr
Asn His Tyr Ile
Asn His Tyr Leu
Asn Ile His Tyr
Asn Ile Asn Trp
Asn Ile Trp Asn
Asn Ile Tyr His
Asn Leu His Tyr
Asn Leu Asn Trp
Asn Leu Trp Asn
Asn Leu Tyr His
Asn Asn Ile Trp
Asn Asn Leu Trp
Asn Asn Trp Ile
Asn Asn Trp Leu
Asn Gln Glu Arg
Asn Gln Arg Glu
Asn Gln Val Trp
Asn Gln Trp Val
Asn Arg Ala Trp
Asn Arg Glu Gln
Asn Arg Gln Glu
Asn Arg Trp Ala
Asn Val Gln Trp
Asn Val Trp Gln
Asn Trp Ala Arg
Asn Trp Ile Asn
Asn Trp Leu Asn
Asn Trp Asn Ile
Asn Trp Asn Leu
Asn Trp Gln Val
Asn Trp Arg Ala
Asn Trp Val Gln
Asn Tyr His Ile
Asn Tyr His Leu
Asn Tyr Ile His
Asn Tyr Leu His
Pro Phe Pro Trp
Pro Phe Trp Pro
Pro His His Arg
Pro His Arg His
Pro Ile Met Trp
Pro Ile Trp Met
Pro Leu Met Trp
Pro Leu Trp Met
Pro Met Ile Trp
Pro Met Leu Trp
Pro Met Trp Ile
Pro Met Trp Leu
Pro Pro Phe Trp
Pro Pro Trp Phe
Pro Arg His His
Pro Trp Phe Pro
Pro Trp Ile Met
Pro Trp Leu Met
Pro Trp Met Ile
Pro Trp Met Leu
Pro Trp Pro Phe
Gln Asp Gln Arg
Gln Asp Arg Gln
Gln Glu Asn Arg
Gln Glu Arg Asn
Gln Gly Arg Trp
Gln Gly Trp Arg
Gln His Val Tyr
Gln His Tyr Val
Gln Asn Glu Arg
Gln Asn Arg Glu
Gln Asn Val Trp
Gln Asn Trp Val
Gln Gln Asp Arg
Gln Gln Arg Asp
Gln Arg Asp Gln
Gln Arg Glu Asn
Gln Arg Gly Trp
Gln Arg Asn Glu
Gln Arg Gln Asp
Gln Arg Trp Gly
Gln Val His Tyr
Gln Val Asn Trp
Gln Val Trp Asn
Gln Val Tyr His
Gln Trp Gly Arg
Gln Trp Asn Val
Gln Trp Arg Gly
Gln Trp Val Asn
Gln Tyr His Val
Gln Tyr Val His
Arg Ala His Tyr
Arg Ala Asn Trp
Arg Ala Trp Asn
Arg Ala Tyr His
Arg Asp Gln Gln
Arg Glu Glu Ile
Arg Glu Glu Leu
Arg Glu Ile Glu
Arg Glu Leu Glu
Arg Glu Asn Gln
Arg Glu Gln Asn
Arg Phe His Ser
Arg Phe Ser His
Arg Gly Gln Trp
Arg Gly Trp Gln
Arg His Ala Tyr
Arg His Phe Ser
Arg His His Pro
Arg His Pro His
Arg His Ser Phe
Arg His Tyr Ala
Arg Ile Glu Glu
Arg Leu Glu Glu
Arg Asn Ala Trp
Arg Asn Glu Gln
Arg Asn Trp Ala
Arg Pro His His
Arg Gln Asp Gln
Arg Gln Glu Asn
Arg Gln Gly Trp
Arg Gln Gln Asp
Arg Gln Trp Gly
Arg Ser Phe His
Arg Ser His Phe
Arg Trp Ala Asn
Arg Trp Gly Gln
Arg Trp Asn Ala
Arg Trp Gln Gly
Arg Tyr Ala His
Arg Tyr His Ala
Ser Phe His Arg
Ser Phe Arg His
Ser His Phe Arg
Ser His Arg Phe
Ser Arg Phe His
Ser Arg His Phe
Val His Gln Tyr
Val His Tyr Gln
Val Asn Gln Trp
Val Asn Trp Gln
Val Gln His Tyr
Val Gln Asn Trp
Val Gln Trp Asn
Val Gln Tyr His
Val Trp Asn Gln
Val Trp Gln Asn
Val Tyr His Gln
Val Tyr Gln His
Trp Ala Asn Arg
Trp Ala Arg Asn
Trp Phe Pro Pro
Trp Gly Gln Arg
Trp Gly Arg Gln
Trp Ile Met Pro
Trp Ile Asn Asn
Trp Ile Pro Met
Trp Leu Met Pro
Trp Leu Asn Asn
Trp Leu Pro Met
Trp Met Ile Pro
Trp Met Leu Pro
Trp Met Pro Ile
Trp Met Pro Leu
Trp Asn Ala Arg
Trp Asn Ile Asn
Trp Asn Leu Asn
Trp Asn Asn Ile
Trp Asn Asn Leu
Trp Asn Gln Val
Trp Asn Arg Ala
Trp Asn Val Gln
Trp Pro Phe Pro
Trp Pro Ile Met
Trp Pro Leu Met
Trp Pro Met Ile
Trp Pro Met Leu
Trp Pro Pro Phe
Trp Gln Gly Arg
Trp Gln Asn Val
Trp Gln Arg Gly
Trp Gln Val Asn
Trp Arg Ala Asn
Trp Arg Gly Gln
Trp Arg Asn Ala
Trp Arg Gln Gly
Trp Val Asn Gln
Trp Val Gln Asn
Tyr Ala His Arg
Tyr Ala Arg His
Tyr His Ala Arg
Tyr His Ile Asn
Tyr His Leu Asn
Tyr His Asn Ile
Tyr His Asn Leu
Tyr His Gln Val
Tyr His Arg Ala
Tyr His Val Gln
Tyr Ile His Asn
Tyr Ile Asn His
Tyr Leu His Asn
Tyr Leu Asn His
Tyr Asn His Ile
Tyr Asn His Leu
Tyr Asn Ile His
Tyr Asn Leu His
Tyr Gln His Val
Tyr Gln Val His
Tyr Arg Ala His
Tyr Arg His Ala
Tyr Val His Gln
Tyr Val Gln His
N-[(3a,5b,7a,12a)-3,12-dihydroxy-24-oxo-7-(sulfoxy)cholan-24-yl]-Glycine
N-[(3a,5b,7a,12a)-3,7-dihydroxy-24-oxo-12-(sulfoxy)cholan-24-yl]-Glycine
N-[(3a,5b,7a,12a)-3,12-dihydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-Glycine
N-[(3a,5b,7a,12a)-3,7-dihydroxy-24-oxo-12-(sulfooxy)cholan-24-yl]-Glycine
Landiolol Hydrochloride
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting beta-blocker (β1/β2 selectivity?=?255:1, a half-life of 4?min), acts as an adrenoceptor antagonist[1].
Colforsin daropate hydrochloride
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents D007155 - Immunologic Factors
17-Aminogeldanamycin
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
3alpha-Sulfooxy-7alpha,12alpha-dihydroxy-5beta-cholan-24-oyl-glycine
[(4E,6Z,10E)-19-amino-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
3-(1,3-benzodioxol-5-yl)-1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
N-[[(2R,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(2S,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(2S,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(2R,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(2S,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(2S,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(2R,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(2R,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide
3-(1,3-benzodioxol-5-yl)-1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(1,3-benzodioxol-5-yl)-1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(2-pyrrolidin-1-ylethylamino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-3-cyanobenzamide
3-(1,3-benzodioxol-5-yl)-1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(1,3-benzodioxol-5-yl)-1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(1,3-benzodioxol-5-yl)-1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-methoxybenzenesulfonamide
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-methoxybenzenesulfonamide
N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-methoxybenzenesulfonamide
N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-methoxybenzenesulfonamide
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-methoxybenzenesulfonamide
3-(1,3-benzodioxol-5-yl)-1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
2-[[(4R)-4-[(3R,5S,7R,10S,12S,13R,17R)-3,7-dihydroxy-10,13-dimethyl-12-sulooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
2-amino-3-[hydroxy-[2-hydroxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropoxy]phosphoryl]oxypropanoic acid
1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoserine
(2s,3s,6s,12s)-12-hydroxy-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3r)-3-hydroxy-3-(4-methylpentyl)butanedioate
4,18-bis(acetyloxy)-9,10,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl 2-methylbutanoate
(1r,3r,4s,5r,8s,9r,10r,11s,14s,16s,17r,18r,19r)-4,18-bis(acetyloxy)-9,10,19-trihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl (2r)-2-methylbutanoate
(2s,3s,6s)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (2s,3r)-2,3-dihydroxy-3-(4-methylpentyl)butanedioate
(1s,4r,5s,6r,8e,10r,11e,13e)-3,17-dihydroxy-6,8,10,12,14,18-hexamethyl-4-(2-methylpropyl)-2-azatetracyclo[18.3.1.0¹,⁵.0¹⁶,²¹]tetracosa-2,8,11,13,16,18,20-heptaene-7,15,22,24-tetrone
asterin a; me ester
{"Ingredient_id": "HBIN017184","Ingredient_name": "asterin a; me ester","Alias": "NA","Ingredient_formula": "C26H35N5O8","Ingredient_Smile": "NA","Ingredient_weight": "545.58","OB_score": "NA","CAS_id": "151964-52-2","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "6555","PubChem_id": "NA","DrugBank_id": "NA"}
asterin B
{"Ingredient_id": "HBIN017185","Ingredient_name": "asterin B","Alias": "asterin b","Ingredient_formula": "C26H35N5O8","Ingredient_Smile": "CNC1CCC2(C3CC4=C5C2(C1OC5=CC=C4)CCN3CC6CC6)O","Ingredient_weight": "545.58","OB_score": "8.984232865","CAS_id": "151964-52-2","SymMap_id": "SMIT11503;SMIT14398","TCMID_id": "1923","TCMSP_id": "MOL010452","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
asterinin a; me ester
{"Ingredient_id": "HBIN017187","Ingredient_name": "asterinin a; me ester","Alias": "NA","Ingredient_formula": "C26H35N5O8","Ingredient_Smile": "NA","Ingredient_weight": "545.58","OB_score": "NA","CAS_id": "157536-41-9","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "6553","PubChem_id": "NA","DrugBank_id": "NA"}
asterinin c
{"Ingredient_id": "HBIN017188","Ingredient_name": "asterinin c","Alias": "NA","Ingredient_formula": "C26H35N5O8","Ingredient_Smile": "CCC(C(=O)NC(CO)C(=O)NC(CC(=O)NC(C(C)O)C(=O)OC)C1=CC=CC=C1)NC(=O)C2=CC=CN2","Ingredient_weight": "545.58","OB_score": "NA","CAS_id": "157605-23-7","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "6552","PubChem_id": "101667553","DrugBank_id": "NA"}